SCHEDULE: Morgan Stanley Discloses 8.4% Stake in Chemomab
Beneficial Ownership Report
Morgan Stanley and its subsidiary have disclosed beneficial ownership of 8.4% of Chemomab Therapeutics Ltd.'s Ordinary Shares/American Depositary Shares.
Summary
- Morgan Stanley, along with its wholly-owned subsidiary Morgan Stanley & Co. LLC, has filed a Schedule 13G.
- The filing indicates beneficial ownership of 32,282,680 Ordinary Shares / American Depositary Shares of Chemomab Therapeutics Ltd. by Morgan Stanley.
- This aggregate amount represents 8.4% of the class of securities.
- Morgan Stanley & Co. LLC beneficially owns 28,786,680 shares, representing 7.5% of the class.
- Both entities report shared voting and shared dispositive power over their respective holdings.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 6
Explanation: The filing is a factual disclosure of beneficial ownership. A significant stake by a major institution can be viewed as a positive signal of confidence, but the filing itself does not contain operational or financial performance data to assess sentiment beyond this.
Positives
- A major financial institution like Morgan Stanley holding a significant stake (8.4%) may signal institutional confidence in Chemomab Therapeutics Ltd.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Chemomab Therapeutics Ltd.'s future performance or operations.
Industry Context
The disclosure of a significant stake by a major financial institution like Morgan Stanley in a biotechnology company such as Chemomab Therapeutics Ltd. is a common occurrence in the financial markets, reflecting portfolio investment decisions rather than direct operational involvement. It indicates a passive investment position within the broader healthcare and biotech investment landscape.
Stakeholder Impact
- Shareholders may view the significant stake by Morgan Stanley as a positive indicator of institutional interest and confidence in Chemomab Therapeutics Ltd.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which requires filing of this statement |
| 08/07/2025 | Date of filing and signature by Morgan Stanley and Morgan Stanley & Co. LLC |
Keywords
Chemomab Therapeutics, Morgan Stanley, Schedule 13G, Beneficial Ownership, Institutional Investment, CMAB, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.